Rodman & Renshaw Announces Panel Discussion on Wound Care

Panel Discussion to be Held Thursday, November 11th at the Rodman & Renshaw NYC Headquarters

NEW YORK--(BUSINESS WIRE)-- Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), today announced that Rodman will host Oxygen Biotherapeutics (NASDAQ: OXBT), Oculus Innovative Sciences (NASDAQ: OCLS), RegeneRx (AMEX: RGN), Cytomedix (AMEX: GTF), Derma Sciences, Inc (NASDAQ: DSCI), and Uluru (AMEX: ULU) for a panel discussion in Rodman’s media center, on November 11, 2010. The event will be moderated by Michael Higgins, Senior Specialty Pharmaceuticals Analyst, and Suraj Kalia, Senior Medical Devices Analyst at Rodman & Renshaw, LLC.

The topics to be covered will include the increase in the number of chronic wounds treated by physicians in hospitals and clinics, developing technologies and products used to address these issues, and innovative solutions that may be overlooked by investors in the space. Panel members will also discuss upcoming catalysts, challenges in obtaining approval for their pipeline products, and prospective Advanced Wound Care guidelines for clinical trial design.

The panel will take place at the Rodman & Renshaw Offices at 4:30PM on Thursday, November 11th. To attend, please RSVP to Jake Rynar at [email protected].

Investors are welcome to attend in person. Please respond as space is limited. This event also will be webcast live for RodmanTV registered users at http://rodm.tv/broadcast.php. RodmanTV is a service for institutional investors and corporations that have a relationship with the firm. In addition, there will be conference call access (please contact your Rodman representative to get your dial-in number), and a replay of the discussion will be made available at www.rodm.tv twenty-four hours after completion of the event.

About Rodman & Renshaw

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

For more information visit Rodman & Renshaw on the Internet at www.rodm.com

Rodman & Renshaw, LLC ("Rodman") reserves the right in its sole discretion to accept or reject registration for, or admission to, all or any portion of our panel discussions. Rodman sponsors the Wound Care Panel discussion. Rodman does not prepare, review or edit the presentations and other information provided by the participating corporations, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance to this panel discussion, nor is Rodman soliciting any offers to buy or sell any security of participating corporations. Member FINRA, SIPC.



CONTACT:

Rodman & Renshaw Investor Relations
Grayling
Mr. Christopher Chu, 646-284-9400 (ext. 426)
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Infectious Diseases  Medical Devices  Pharmaceutical  Professional Services  Finance  Medical Supplies

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.